{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:28:14Z","timestamp":1786422494080,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20421"],"award-info":[{"award-number":["U23A20421"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171189"],"award-info":[{"award-number":["82171189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-026-04097-0","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:57:56Z","timestamp":1779299876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Xanomeline-trospium reverses phencyclidine-induced cognitive deficits through modulation of the gut microbiota-brain axis in mice"],"prefix":"10.1038","volume":"16","author":[{"given":"Xin","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumi","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6785-9627","authenticated-orcid":false,"given":"Jian-Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-0439","authenticated-orcid":false,"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"4097_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrd3628","volume":"11","author":"MJ Millan","year":"2012","unstructured":"Millan MJ, Agid Y, Br\u00fcne M, Bullmore ET, Carter CS, Clayton NS, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012;11:141\u201368. https:\/\/doi.org\/10.1038\/nrd3628.","journal-title":"Nat Rev Drug Discov"},{"key":"4097_CR2","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/nrn4005","volume":"16","author":"MF Green","year":"2015","unstructured":"Green MF, Horan WP, Lee J. Social cognition in schizophrenia. Nat Rev Neurosci. 2015;16:620\u201331. https:\/\/doi.org\/10.1038\/nrn4005.","journal-title":"Nat Rev Neurosci"},{"key":"4097_CR3","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00406-022-01416-6","volume":"272","author":"Y Gebreegziabhere","year":"2022","unstructured":"Gebreegziabhere Y, Habatmu K, Mihretu A, Cella M, Alem A. Cognitive impairment in people with schizophrenia: an umbrella review. Eur Arch Psychiatry Clin Neurosci. 2022;272:1139\u201355. https:\/\/doi.org\/10.1007\/s00406-022-01416-6.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"4097_CR4","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","volume":"28","author":"RA McCutcheon","year":"2023","unstructured":"McCutcheon RA, Keefe RSE, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry. 2023;28:1902\u201318. https:\/\/doi.org\/10.1038\/s41380-023-01949-9.","journal-title":"Mol Psychiatry"},{"key":"4097_CR5","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s00406-023-01570-5","volume":"273","author":"K Hashimoto","year":"2023","unstructured":"Hashimoto K. Arketamine for cognitive impairment in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci. 2023;273:1513\u201325. https:\/\/doi.org\/10.1007\/s00406-023-01570-5.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"4097_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev-pharmtox-051921-093250","volume":"63","author":"DC Javitt","year":"2023","unstructured":"Javitt DC. Cognitive impairment associated with schizophrenia: from pathophysiology to treatment. Ann Rev Pharmacol Toxicol. 2023;63:199\u2013141. https:\/\/doi.org\/10.1146\/annurev-pharmtox-051921-093250.","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"4097_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41537-020-0102-z","volume":"6","author":"IE Sommer","year":"2020","unstructured":"Sommer IE, Tiihonen J, van Mourik A, Tanskanen A, Taipale H. The clinical course of schizophrenia in women and men-a nation-wide cohort study. NPJ Schizophr. 2020;6:12. https:\/\/doi.org\/10.1038\/s41537-020-0102-z.","journal-title":"NPJ Schizophr"},{"key":"4097_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41537-020-00120-5","volume":"6","author":"R Ayesa-Arriola","year":"2020","unstructured":"Ayesa-Arriola R, de la Foz VO, Seti\u00e9n-Suero E, Ram\u00edrez-Bonilla ML, Su\u00e1rez-Pinilla P, Son JM, et al. Understanding sex differences in long-term outcomes after a first episode of psychosis. NPJ Schizophr. 2020;6:33. https:\/\/doi.org\/10.1038\/s41537-020-00120-5.","journal-title":"NPJ Schizophr"},{"key":"4097_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-021-00347-1","volume":"20","author":"N Zhao","year":"2021","unstructured":"Zhao N, Wang XH, Kang CY, Zheng Y, Yang LY, Guan TF, et al. Sex differences in association between cognitive impairment and clinical correlates in Chinese patients with first-episode drug-na\u00efve schizophrenia. Ann Gen Psychiatry. 2021;20:26. https:\/\/doi.org\/10.1186\/s12991-021-00347-1.","journal-title":"Ann Gen Psychiatry"},{"key":"4097_CR10","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","volume":"179","author":"SM Paul","year":"2022","unstructured":"Paul SM, Yohn SE, Popiolek M, Miller AC, Felder CC. Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry. 2022;179:611\u201327. https:\/\/doi.org\/10.1176\/appi.ajp.21101083.","journal-title":"Am J Psychiatry"},{"key":"4097_CR11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.biopsych.2024.03.014","volume":"96","author":"SM Paul","year":"2024","unstructured":"Paul SM, Yohn SE, Brannan SK, Neugebauer NM, Breier A. Muscarinic receptor activators as novel treatments for schizophrenia. Biol Psychiatry. 2024;96:627\u201337. https:\/\/doi.org\/10.1016\/j.biopsych.2024.03.014.","journal-title":"Biol Psychiatry"},{"key":"4097_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","volume":"403","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024;403:160\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(23)02190-6.","journal-title":"Lancet"},{"key":"4097_CR13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","volume":"81","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Walling DP, Tamminga CA, Breier A, Zhu H, et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2024;81:749\u201356. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.0785.","journal-title":"JAMA Psychiatry"},{"key":"4097_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/d41586-024-03123-9","volume":"634","author":"E Dolgin","year":"2024","unstructured":"Dolgin E. Revolutionary drug for schizophrenia wins US approval. Nature. 2024;634:276\u20137. https:\/\/doi.org\/10.1038\/d41586-024-03123-9.","journal-title":"Nature"},{"key":"4097_CR15","doi-asserted-by":"publisher","first-page":"ldaf016","DOI":"10.1093\/bmb\/ldaf016","volume":"156","author":"M Lyman","year":"2025","unstructured":"Lyman M, McCutcheon RA. Antipsychotic drugs at 75: the past, present, and future of psychosis management. Br Med Bull. 2025;156:ldaf016. https:\/\/doi.org\/10.1093\/bmb\/ldaf016.","journal-title":"Br Med Bull"},{"key":"4097_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1176\/appi.ajp.20240076","volume":"182","author":"WP Horan","year":"2025","unstructured":"Horan WP, Sauder C, Harvey PD, Ramsay IS, Yohn SE, Keefe RSE, et al. The impact of xanomeline and trospium chloride on cognitive impairment in acute schizophrenia: replication in pooled data from two phase 3 trials. Am J Psychiatry. 2025;182:297\u2013306. https:\/\/doi.org\/10.1176\/appi.ajp.20240076.","journal-title":"Am J Psychiatry"},{"key":"4097_CR17","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1176\/appi.ajp.20250021","volume":"182","author":"R Tandon","year":"2025","unstructured":"Tandon R. Does xanomeline\/trospium have unique benefits for cognitive impairment associated with schizophrenia?. Am J Psychiatry. 2025;182:878. https:\/\/doi.org\/10.1176\/appi.ajp.20250021.","journal-title":"Am J Psychiatry"},{"key":"4097_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1176\/appi.ajp.20241187","volume":"182","author":"DC Javitt","year":"2025","unstructured":"Javitt DC. Xanomeline-trospium treatment of cognitive impairments of schizophrenia: hope for some, or hope for all?. Am J Psychiatry. 2025;182:237\u20139. https:\/\/doi.org\/10.1176\/appi.ajp.20241187.","journal-title":"Am J Psychiatry"},{"key":"4097_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pnpbp.2013.11.008","volume":"49","author":"JW Brown","year":"2014","unstructured":"Brown JW, Rueter LE, Zhang M. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically. Prog Neuropsychopharmacol Biol Psychiatry. 2014;49:53\u201362. https:\/\/doi.org\/10.1016\/j.pnpbp.2013.11.008.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"4097_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neuroscience.2019.07.003","volume":"414","author":"T Mandai","year":"2019","unstructured":"Mandai T, Kasahara M, Kurimoto E, Tanaka M, Suzuki M, Nakatani A, et al. In vivo pharmacological comparison of TAK-071, a positive allosteric modulator of muscarinic M1 receptor, and xanomeline, an agonist of muscarinic M1\/M4 receptor, in rodents. Neuroscience. 2019;414:60\u201376. https:\/\/doi.org\/10.1016\/j.neuroscience.2019.07.003.","journal-title":"Neuroscience"},{"key":"4097_CR21","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/s41386-020-00916-0","volume":"46","author":"C Montani","year":"2021","unstructured":"Montani C, Canella C, Schwarz AJ, Li J, Gilmour G, Galbusera A, et al. The M1\/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain. Neuropsychopharmacology. 2021;46:1194\u2013206. https:\/\/doi.org\/10.1038\/s41386-020-00916-0.","journal-title":"Neuropsychopharmacology"},{"key":"4097_CR22","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1038\/s41380-019-0475-4","volume":"25","author":"F Zhu","year":"2020","unstructured":"Zhu F, Guo R, Wang W, Ju Y, Wang Q, Ma Q, et al. Transplantation of microbiota from drug-free patients with schizophrenia causes schizophrenia-like abnormal behaviors and dysregulated kynurenine metabolism in mice. Mol Psychiatry. 2020;25:2905\u201318. https:\/\/doi.org\/10.1038\/s41380-019-0475-4.","journal-title":"Mol Psychiatry"},{"key":"4097_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15457-9","volume":"11","author":"F Zhu","year":"2020","unstructured":"Zhu F, Ju Y, Wang W, Wang Q, Guo R, Ma Q, et al. Metagenome-wide association of gut microbiome features for schizophrenia. Nat Commun. 2020;11:1612. https:\/\/doi.org\/10.1038\/s41467-020-15457-9.","journal-title":"Nat Commun"},{"key":"4097_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.schres.2020.02.010","volume":"234","author":"JR Kelly","year":"2021","unstructured":"Kelly JR, Minuto C, Cryan JF, Clarke G, Dinan TG. The role of the gut microbiome in the development of schizophrenia. Schizophr Res. 2021;234:4\u201323. https:\/\/doi.org\/10.1016\/j.schres.2020.02.010.","journal-title":"Schizophr Res"},{"key":"4097_CR25","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1038\/s41380-022-01456-3","volume":"27","author":"AJ McGuinness","year":"2022","unstructured":"McGuinness AJ, Davis JA, Dawson SL, Loughman A, Collier F, O\u2019Hely M, et al. A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia. Mol Psychiatry. 2022;27:1920\u201335. https:\/\/doi.org\/10.1038\/s41380-022-01456-3.","journal-title":"Mol Psychiatry"},{"key":"4097_CR26","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1038\/s41380-023-02287-6","volume":"28","author":"K Hashimoto","year":"2023","unstructured":"Hashimoto K. Emerging role of the host microbiome in neuropsychiatric disorders: overview and future directions. Mol Psychiatry. 2023;28:3625\u201337. https:\/\/doi.org\/10.1038\/s41380-023-02287-6.","journal-title":"Mol Psychiatry"},{"key":"4097_CR27","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/schbul\/sbad049","volume":"49","author":"N Murray","year":"2023","unstructured":"Murray N, Al Khalaf S, Bastiaanssen TFS, Kaulmann D, Lonergan E, Cryan JF, et al. Compositional and functional alterations in intestinal microbiota in patients with psychosis or schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2023;49:1239\u201355. https:\/\/doi.org\/10.1093\/schbul\/sbad049.","journal-title":"Schizophr Bull"},{"key":"4097_CR28","doi-asserted-by":"publisher","first-page":"e0005823","DOI":"10.1128\/spectrum.00058-23","volume":"11","author":"L Qian","year":"2023","unstructured":"Qian L, He X, Liu Y, Gao F, Lu W, Fan Y, et al. Longitudinal gut microbiota dysbiosis underlies olanzapine-induced weight gain. Microbiol Spectr. 2023;11:e0005823. https:\/\/doi.org\/10.1128\/spectrum.00058-23.","journal-title":"Microbiol Spectr"},{"key":"4097_CR29","doi-asserted-by":"publisher","first-page":"2418988","DOI":"10.1080\/19490976.2024.2418988","volume":"16","author":"ND Nuzum","year":"2024","unstructured":"Nuzum ND, Deady C, Kittel-Schneider S, Cryan JF, O\u2019Mahony SM, Clarke G. More than just a number: the gut microbiota and brain function across the extremes of life. Gut Microbes. 2024;16:2418988. https:\/\/doi.org\/10.1080\/19490976.2024.2418988.","journal-title":"Gut Microbes"},{"key":"4097_CR30","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1192\/bjp.2024.255","volume":"227","author":"K Hashimoto","year":"2025","unstructured":"Hashimoto K. Host microbiota in clozapine-induced ileus and pneumonia among people with schizophrenia. Br J Psychiatry. 2025;227:574\u20135. https:\/\/doi.org\/10.1192\/bjp.2024.255.","journal-title":"Br J Psychiatry"},{"key":"4097_CR31","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3390\/ijms22020926","volume":"22","author":"Y Tanahashi","year":"2021","unstructured":"Tanahashi Y, Komori S, Matsuyama H, Kitazawa T, Unno T. Functions of muscarinic receptor subtypes in gastrointestinal smooth muscle: a review of studies with receptor-knockout mice. Int J Mol Sci. 2021;22:926. https:\/\/doi.org\/10.3390\/ijms22020926.","journal-title":"Int J Mol Sci"},{"key":"4097_CR32","doi-asserted-by":"publisher","first-page":"6508","DOI":"10.3390\/ijms24076508","volume":"24","author":"J Uwada","year":"2023","unstructured":"Uwada J, Nakazawa H, Muramatsu I, Masuoka T, Yazawa T. Role of muscarinic acetylcholine receptors in intestinal epithelial homeostasis: insights for the treatment of inflammatory bowel disease. Int J Mol Sci. 2023;24:6508. https:\/\/doi.org\/10.3390\/ijms24076508.","journal-title":"Int J Mol Sci"},{"key":"4097_CR33","doi-asserted-by":"publisher","first-page":"124089","DOI":"10.1016\/j.lfs.2025.124089","volume":"384","author":"MA Desouky","year":"2026","unstructured":"Desouky MA, Eldahshan W, Atawia RT. Exploring the gut-lung-brain axis: focus on endothelial dysfunction, impaired bioenergetics, and strategies to mitigate lung and cognitive disorders. Life Sci. 2026;384:124089. https:\/\/doi.org\/10.1016\/j.lfs.2025.124089.","journal-title":"Life Sci"},{"key":"4097_CR34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejphar.2005.07.002","volume":"519","author":"K Hashimoto","year":"2005","unstructured":"Hashimoto K, Fujita Y, Shimizu E, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol. 2005;519:114\u20137. https:\/\/doi.org\/10.1016\/j.ejphar.2005.07.002.","journal-title":"Eur J Pharmacol"},{"key":"4097_CR35","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/sj.npp.1301047","volume":"32","author":"K Hashimoto","year":"2007","unstructured":"Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology. 2007;32:514\u201321. https:\/\/doi.org\/10.1038\/sj.npp.1301047.","journal-title":"Neuropsychopharmacology"},{"key":"4097_CR36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.biopsych.2007.04.034","volume":"63","author":"K Hashimoto","year":"2008","unstructured":"Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biol Psychiatry. 2008;63:92\u201397. https:\/\/doi.org\/10.1016\/j.biopsych.2007.04.034.","journal-title":"Biol Psychiatry"},{"key":"4097_CR37","doi-asserted-by":"publisher","first-page":"172839","DOI":"10.1016\/j.pbb.2019.172839","volume":"188","author":"Y Tan","year":"2020","unstructured":"Tan Y, Fujita Y, Qu Y, Chang L, Pu Y, Wang S, et al. Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: role of BDNF-TrkB signaling. Pharmacol Biochem Behav. 2020;188:172839. https:\/\/doi.org\/10.1016\/j.pbb.2019.172839.","journal-title":"Pharmacol Biochem Behav"},{"key":"4097_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120885","volume":"307","author":"Y Hashimoto","year":"2022","unstructured":"Hashimoto Y, Eguchi A, Wei Y, Shinno-Hashimoto H, Fujita Y, Ishima T, et al. Antibiotic-induced microbiome depletion improves LPS-induced acute lung injury via gut-lung axis. Life Sci. 2022;307:120885. https:\/\/doi.org\/10.1016\/j.lfs.2022.120885.","journal-title":"Life Sci"},{"key":"4097_CR39","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1080\/19490976.2019.1701352","volume":"11","author":"J Triplett","year":"2020","unstructured":"Triplett J, Ellis D, Braddock A, Roberts E, Ingram K, Perez E, et al. Temporal and region-specific effects of sleep fragmentation on gut microbiota and intestinal morphology in sprague dawley rats. Gut Microbes. 2020;11:706\u201320. https:\/\/doi.org\/10.1080\/19490976.2019.1701352.","journal-title":"Gut Microbes"},{"key":"4097_CR40","doi-asserted-by":"publisher","first-page":"111223","DOI":"10.1016\/j.pnpbp.2024.111223","volume":"136","author":"D Xu","year":"2025","unstructured":"Xu D, Eguchi A, Murayama R, Liu G, Zhao M, Zhu T, et al. Effects of 3,4-methylenedioxymethamphetamine on the gut microbiota and metabolites in the small intestine, cecum, and colon of male rats. Prog Neuropsychopharmacol Biol Psychiatry. 2025;136:111223 https:\/\/doi.org\/10.1016\/j.pnpbp.2024.111223.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"4097_CR41","doi-asserted-by":"publisher","first-page":"177345","DOI":"10.1016\/j.ejphar.2025.177345","volume":"991","author":"M Zhao","year":"2025","unstructured":"Zhao M, Eguchi A, Murayama R, Xu D, Zhu T, Xu B, et al. Repeated intermittent administration of 3,4-methylenedioxymethamphetamine mitigates demyelination in the brain from cuprizone-treated mice. Eur J Pharmacol. 2025;991:177345. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177345.","journal-title":"Eur J Pharmacol"},{"key":"4097_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-6-r60","volume":"12","author":"N Segata","year":"2011","unstructured":"Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12:R60. https:\/\/doi.org\/10.1186\/gb-2011-12-6-r60.","journal-title":"Genome Biol"},{"key":"4097_CR43","doi-asserted-by":"publisher","first-page":"1130689","DOI":"10.3389\/fendo.2023.1130689","volume":"14","author":"JA Rusch","year":"2023","unstructured":"Rusch JA, Layden BT, Dugas LR. Signalling cognition: the gut microbiota and hypothalamic-pituitary-adrenal axis. Front Endocrinol. 2023;14:1130689. https:\/\/doi.org\/10.3389\/fendo.2023.1130689.","journal-title":"Front Endocrinol"},{"key":"4097_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-02627-2","volume":"15","author":"C Cao","year":"2025","unstructured":"Cao C, Li S, Wang W, Shi L, Ma R, Zhang B, et al. Intestinal microbiota improves inflammation and cognitive function in the brain of a7nAChR deficient rat through the gut brain axis. Sci Rep. 2025;15:18381. https:\/\/doi.org\/10.1038\/s41598-025-02627-2.","journal-title":"Sci Rep"},{"key":"4097_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrmicro3552","volume":"14","author":"GP Donaldson","year":"2016","unstructured":"Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev Microbiol. 2016;14:20\u201332. https:\/\/doi.org\/10.1038\/nrmicro3552.","journal-title":"Nat Rev Microbiol"},{"key":"4097_CR46","doi-asserted-by":"publisher","first-page":"101190","DOI":"10.1016\/j.xcrm.2023.101190","volume":"4","author":"BAH Jensen","year":"2023","unstructured":"Jensen BAH, Heyndrickx M, Jonkers D, Mackie A, Millet S, Naghibi M, et al. Small intestine vs. colon ecology and physiology: why it matters in probiotic administration. Cell Rep Med. 2023;4:101190. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101190.","journal-title":"Cell Rep Med"},{"key":"4097_CR47","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/sj.npp.1300210","volume":"28","author":"TJ Raedler","year":"2003","unstructured":"Raedler TJ, Knable MB, Jones DW, Urbina RA, Egan MF, Weinberger DR. Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology. 2003;28:1531\u20137. https:\/\/doi.org\/10.1038\/sj.npp.1300210.","journal-title":"Neuropsychopharmacology"},{"key":"4097_CR48","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/02698811251319458","volume":"39","author":"PD Morrison","year":"2025","unstructured":"Morrison PD, Jauhar S, Young AH. The mechanisms of action of clozapine. J Psychopharmacol. 2025;39:297\u2013300. https:\/\/doi.org\/10.1177\/02698811251319458.","journal-title":"J Psychopharmacol"},{"key":"4097_CR49","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.biopsych.2025.06.011","volume":"99","author":"RM Murray","year":"2025","unstructured":"Murray RM, Egerton A, Gao Y, Grace AA, Howes O, Jauhar S, et al. Why is clozapine uniquely effective in treatment-resistant schizophrenia? A review and proposal. Biol Psychiatry. 2025;99:517\u201326. https:\/\/doi.org\/10.1016\/j.biopsych.2025.06.011.","journal-title":"Biol Psychiatry"},{"key":"4097_CR50","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1176\/appi.ajp.20230744","volume":"181","author":"JJ Partanen","year":"2024","unstructured":"Partanen JJ, H\u00e4pp\u00f6l\u00e4 P, K\u00e4mpe A, Ahola-Olli A, Hellsten A, Rask SM, et al. High burden of ileus and pneumonia in clozapine-treated individuals with schizophrenia: a finnish 25-year follow-up register study. Am J Psychiatry. 2024;181:879\u201392. https:\/\/doi.org\/10.1176\/appi.ajp.20230744.","journal-title":"Am J Psychiatry"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04097-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04097-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04097-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T03:41:13Z","timestamp":1786419673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04097-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4097"],"URL":"https:\/\/doi.org\/10.1038\/s41398-026-04097-0","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Hashimoto is the inventor of filed patent applications on \u201cThe use of\n                      R\n                      -Ketamine in the treatment of psychiatric diseases\u201d, \u201c(\n                      S\n                      )-norketamine and salt thereof as pharmaceutical\u201d, \u201c\n                      R\n                      -Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder\u201d, \u201cPreventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases\u201d, and \u201c\n                      R\n                      -Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder\u201d by the Chiba University. Dr. Hashimoto has also received research support from Otsuka (Tokyo, Japan). The other authors declare no competing interests related to this study.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"409"}}